NCT04179409View on ClinicalTrials.gov

A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2023

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Amondys 45

This drug is used to target skipping of exon 45 of the dystrophin gene.

DRUG

Exondys 51

This drug is used to target skipping of exon 51 of the dystrophin gene.

DRUG

Vyondys 53

This drug is used to target skipping of exon 53 of the dystrophin gene.

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

All Listed Sponsors
collaborator

Sarepta Therapeutics, Inc.

INDUSTRY

lead

Kevin Flanigan

OTHER

NCT04179409 - A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications. | Biotech Hunter | Biotech Hunter